Form 4: Silo Pharma Director Wayne Linsley Granted 50,000 Stock Options Under Equity Incentive Plan

Silo Pharma, Inc. Director Wayne Linsley was granted 50,000 stock options with an exercise price of $0.429, vesting one year from the grant date, under the company's 2020 Omnibus Equity Incentive Plan.

Summary

• Wayne Linsley, a Director of Silo Pharma, Inc. (SILO), was granted 50,000 stock options.
• The options have an exercise price of $0.429 per share.
• The grant date for these options was May 23, 2025.
• The options were issued under the Issuer's 2020 Omnibus Equity Incentive Plan.
• One hundred percent (100%) of the shares subject to the option will vest on the one-year anniversary of the grant date, specifically May 23, 2026.
• The options have an expiration date of May 23, 2035.
• Following this transaction, Wayne Linsley beneficially owns a total of 53,425 derivative securities (options).

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a standard practice that aligns management's interests with shareholders, generally viewed as a neutral to slightly positive event for corporate governance and incentive alignment.

Positives

• The grant of stock options to Director Wayne Linsley aligns his interests with those of shareholders, incentivizing long-term company performance.
• The options were issued under an existing and approved 2020 Omnibus Equity Incentive Plan, indicating a structured approach to executive compensation.

Negatives

• No specific negative aspects are identified in this routine equity grant filing.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

The granted options are set to vest on May 23, 2026, aligning the director's future compensation with the company's performance over the next year.

Industry Context

The granting of stock options to directors is a common practice across various industries, particularly in biotechnology and pharmaceutical sectors, to attract and retain talent and align management incentives with shareholder value creation.

Comparison to Industry Standards

• Equity-based compensation, such as stock options, is a standard component of director remuneration in publicly traded companies, especially those in growth-oriented sectors like pharmaceuticals.
• The vesting schedule of one year for 100% of the options is a common structure for director grants, aiming to incentivize short-to-medium term performance and retention.
• The exercise price of $0.429, likely the market price on the grant date, is typical for 'at-the-money' option grants.

Corporate Governance

Related Party Transactions

• The transaction involves the grant of stock options to Wayne Linsley, a Director of Silo Pharma, Inc., which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's financial interests with shareholder value creation, potentially leading to improved long-term performance.
• Employees: While not directly impacting all employees, such grants are part of a broader compensation strategy that can influence overall company culture and talent retention.

Next Steps

• The options granted to Director Wayne Linsley are scheduled to vest on May 23, 2026.

Key Dates

Recommendation

Keywords

Silo Pharma, SILO, Form 4, stock options, equity incentive plan, director compensation, beneficial ownership, insider transaction